text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 259793-96-9 | Product Number: F1296

Favipiravir


Purity: >98.0%(HPLC)
Synonyms:
  • T-705
  • 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide
  • 6-Fluoro-3-hydroxypyrazine-2-carboxamide
Product Documents:
25MG
€72.00
1   ≥40 
100MG
€173.00
Contact Us ≥60 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Supplemental Product Information:

This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.

Product Number F1296
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__5H__4FN__3O__2 = 157.10 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive,Heat Sensitive
Packaging and Container 25MG-Glass Bottle with Plastic Insert (View image)
CAS RN 259793-96-9
Reaxys Registry Number 9697246
MDL Number

MFCD12032148

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Melting point 190.0 to 194.0 °C
Properties (reference)
Melting Point 192 °C
Solubility (slightly sol. in) Methanol
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H361 : Suspected of damaging fertility or the unborn child.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
Related Laws:
RTECS# UQ2281100
Transport Information:
HS Number 2933599590
Application
Favipiravir: A Potent and Selective Viral RNA Polymerase Inhibitor

Favipiravir (T-705) is an antiviral agent developed by Shiraki, et al. It has been found to have potent and selective inhibitory activity against RNA-dependent RNA polymerase of RNA viruses, such as influenza A, B, and C viruses.1-4) Its ribose-5’-triphosphate is the active metabolite, and it is recognized by virus RNA polymerase as a substrate competing with guanosine 5'-triphosphate (GTP), giving inhibition of viral RNA synthesis. On the other hand, it has been pointed out that favipiravir has a risk for teratogenicity and embryotoxicity.4) Recently, favipiravir has been also reported to show potential anti Ebola virus and coronavirus (SARS-CoV-2) activities.4-7) For your reference, T-1105 [H1485], an antiviral agent, is an analog replacing the 6-fluoro atom to hydrogen. (The product is for research purpose only.)

References


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.